Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Aslan Soars 186% After Journal Reports New Acute Myeloid Leukemia Data

Article By:
The Fly
Saturday, November 23, 2019 11:10 AM EDT
Aslan Pharmaceuticals announced that new preclinical data characterizing ASLAN003 as a potential treatment for acute myeloid leukemia has been published in the November issue of Haematologica Journal which sent shares surging higher.
In this article: ASLN
Week In Review: BeiGene's BTK Inhibitor Approved In US And China Approval For PD-1 Expected In Two Months

Article By:
ChinaBio® Today
Saturday, November 16, 2019 4:09 PM EDT
Beijing's BeiGene had an outstanding week: its BTK drug, Brukinsa™, was approved for US use to treat mantle cell lymphoma, and its PD-1 candidate is poised for China approval before the end of the year to treat classical Hodgkin’s lymphoma.
Week In Review: Nanjing's NJCTTQ Agrees To $4 Billion Package For Abpro Bi-Specific Immunotherapies

Article By:
ChinaBio® Today
Saturday, March 2, 2019 4:14 PM EDT
NJCTTQ, a Nanjing biopharma, announced a deal worth up to $4 billion to co-develop bispecific immunotherapies discovered by Abpro of Massachusetts.